Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets

NCT01226056 is registered in ClinicalTrials.gov with Southern Europe New Drug Organization as lead sponsor.

NCT NCT01226056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01226056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets
Lead sponsor
Southern Europe New Drug Organization
Phase
Phase 1/2
Overall status
Suspended
Start date
March 31, 2009
Completion date
December 31, 2012
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors